Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Bioavailability Enhancement of Poorly Water-Soluble Drugs: Biopharmaceutics and Technology"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (15 December 2019) | Viewed by 23392
Special Issue Editor
Interests: controlled bioavailability of poorly soluble and poorly absorbable drugs; solubilization, formulation, and development of patient-centric dosage forms; advanced nano-based delivery systems using fattigation (fatty acid conjugation) and click chemistry
Special Issues, Collections and Topics in MDPI journals
Topical Collection in Pharmaceutics: Advanced Pharmaceutical Science and Technology in Korea
Special Issue Information
It is well-known that approximately 40% of marketed approved drugs and about 90% of molecules in the drug discovery pipeline are poorly water-soluble. In the last decade, emerging trends in combinatorial chemistry and drug design have rendered newly developed drug molecules with higher lipophilicity, larger molecular weight, and poor water solubility. As a result, the majority of new drug development results in failure due to the poor water solubility of the drug molecules. Biopharmaceutics is comprised of the adsorption, distribution, metabolism, and elimination (ADME), as well as the impact, of the physicochemical properties of the drug molecules on their in vivo performance and bioavailability.
The optimization of physicochemical properties of such poorly water-soluble molecules for enhanced solubility, dissolution, and ultimately enhanced bioavailability is the most important prerequisite for pharmaceutical researchers to develop drug products. To overcome the poor water solubility of drugs, various approaches to enhance the dissolution rate include solid dispersion, salt formation, supercritical fluid technology, prodrugs, co-crystal formation, cyclodextrin complexes, lipid-based formulations, and nanoparticle drug delivery systems. The continuous development of the new formulation and pharmaceutical technology for poorly water-soluble drugs is highly desired for faster and better development of new drugs. Furthermore, the convergence of diverse technologies is also recommended for the modulation of the release rate and enhanced bioavailability for better patient adherence.
This Special Issue is aimed at highlighting the latest progress and research of pharmaceutical and biopharmaceutical technologies for the enhanced dissolution and bioavailability of poorly water soluble drugs.
Prof. Dr. Beom-Jin Lee
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Poorly water soluble
- Pharmaceutical technology
- Patient adherence